Biocontrol plans IPO (initial public offering) for ThermoChem subsidiary
This article was originally published in Clinica
Executive Summary
Biocontrol Technology, the US minimally-invasive glucose monitoring company which has had an acrimonious relationship with the FDA in an attempt to gain approval for its Diasensor device, is planning to diversify, spinning off a company which offers regional and whole body hyperthermia therapeutic devices.